Ryan Imler
Optometrist · Duncansville, PANPI 1215972146
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,500 of the $10,272 with a category attached, or 63.3%. Alcon accounts for 72.1% of it on its own, with 21 other manufacturers making up the rest. Among optometrist clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $60.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$7K
- Johnson & Johnson Vision Care, Inc.$605
- Oyster Point Pharma, Inc.$343
- Sun Pharmaceutical Industries Inc.$297
- Bausch & Lomb Americas Inc.$291
- Bausch & Lomb, A Division Of Bausch Health US, LLC$220
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$6,50063%
- Food & beverage$3,77237%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 54 | $7,410 |
| Johnson & Johnson Vision Care, Inc. | 25 | $605 |
| Oyster Point Pharma, Inc. | 16 | $343 |
| Sun Pharmaceutical Industries Inc. | 13 | $297 |
| Bausch & Lomb Americas Inc. | 12 | $291 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $220 |
| Biotissue Holdings Inc. | 6 | $202 |
| Novartis | 12 | $198 |
| Maculogix, Inc. | 3 | $147 |
| LKC Technologies, Inc. | 1 | $85 |
| Sight Sciences, Inc. | 2 | $71 |
| AbbVie | 4 | $66 |
| Quidel Corporation | 3 | $60 |
| Kala Pharmaceuticals, Inc. | 3 | $50 |
| ABB Con-cise Optical Group LLC | 2 | $39 |
| Shire North American Group Inc | 2 | $39 |
| Glaukos Corporation | 1 | $32 |
| Coopervision Inc. | 2 | $27 |
| Tarsus Pharmaceuticals, Inc. | 1 | $26 |
| Optos, Inc. | 1 | $24 |
| Ivantis, Inc | 1 | $21 |
| Spark Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Precision 1$6,000
- DAILIES TOTAL1$1,500
- AIR OPTIX$1,000
- Air Optix plus HydraGlyde$1,000
- Dailies Aqua Comfort Plus$1,000
- Precision7$1,000
- INFUSE$125
- Prokera$122
- AmnioGraft$122
- AmnioGuard$122
How this compares
$10,272 in reported general payments places this provider in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 15 | $8,829 |
| Cyclosporine | 24 | $7,638 |
| Prednisolone Acetate | 23 | $1,028 |
| Latanoprost | 56 | $829 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 25 | $522 |
| Timolol Maleate | 26 | $213 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 19 | $180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $291 | $8,82915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Other optometrist in Duncansville
- Gregory CaldwellDuncansville$547K
- James DeomHazle Township$793K
- Leslie O DellNew Freedom$388K
- Kevin BistlinePlymouth Meeting$302K
- Thomas KislanStroudsburg$266K
- Erick HendersonPittsburgh$266K
- Ryan YealyLancaster$164K
- Joseph SmayNew Kensington$147K
- Julie McLaughlinAllentown$142K
- Robert RosenthalNewtown$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.